All In Biotech

Drug Trial Radar · NCT06330038

Anesthesia and Non-small Cell Lung Cancer Recurrence

Recurrence Free Survival After Curative Resection of Non-small Cell Lung Cancer Between Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia: a Multicenter, Randomized, Clinical Trial

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 5,384 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,384

Planned (sponsor's estimate)

Start

Aug 5, 2024

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Seoul National University Hospital; Asan Medical Center; Severance Hospital; Seoul St. Mary's Hospital; Korea University Guro Hospital; DongGuk University; Inha University Hospital; Konkuk University Medical Center; Ewha Womans University; Chungnam National University Hospital; University of Virginia; Memorial Sloan Kettering Cancer Center; Yale University; Mayo Clinic; University of Texas Southwestern Medical Center; University Hospitals Coventry and Warwickshire NHS Trust; Khon Kaen University; King Chulalongkorn Memorial Hospital; The Affiliated Hospital of Qingdao University; Beijing Hospital; All India Institute of Medical Sciences
First posted
Mar 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials.

Conditions

  • Non-small Cell Lung Cancer
  • Surgery
  • Anesthesia

Interventions

  • PropofolDrug

    Propofol will be used for the induction and maintenance of general anesthesia.

  • Inhaled anestheticsDrug

    Inhaled anesthetics will be used for the maintenance of general anesthesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence free survivalTime frame: Within 3 year after curative resection for NSCLC

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.